Horm Metab Res 2004; 36(6): 430-435
DOI: 10.1055/s-2004-814582
Review
© Georg Thieme Verlag Stuttgart · New York

Current Views on Imaging of Adrenal Tumors

I.  Ilias 1, 2 , S.  Alesci 1, 3 , K.  Pacak 1
  • 1Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
  • 2Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Patras, Rion-Patras, Greece
  • 3Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
Further Information

Publication History

Received 9 February 2004

Accepted without Revision 9 February 2004

Publication Date:
07 July 2004 (online)

Preview

Abstract

Anatomical imaging modalities (such as computed tomography [CT] or magnetic resonance imaging [MRI]) and functional imaging modalities (that is, nuclear medicine) are used in the evaluation of adrenal glands. The use of CT (unenhanced, followed by contrast-enhanced) evaluation is the cornerstone of imaging of adrenal tumors. Attenuation values of less than 10 Hounsfield units at unenhanced CT are practically diagnostic for adenomas, while attenuation values of greater than 10 HU are not diagnostic of metastatic disease since non-metastatic disease is also a possibility. When lesions cannot be characterized adequately with CT, MRI evaluation (with T1 and T2-weighted sequences and chemical shift and fat-suppression refinements) is sought. Functional nuclear medicine imaging can be of utility in the evaluation of adrenal masses, more particularly for lesions not adequately characterized with CT and MRI. Nuclear medicine techniques are based on physiological and pathophysiological processes (cellular metabolism, tissue perfusion and local synthesis, uptake, storage of hormones and their receptors). Functional imaging aids initial preoperative staging, diagnostic evaluation of suspicious lesions, identification of metastatic or recurrent tumors, refining prognosis, and deciding on and predicting responses to therapy. [131I]-6-iodomethyl norcholesterol scintigraphy can differentiate adenomas from carcinomas. Pheochromocytomas appear as areas of abnormal/increased [131I]- and [123I]-meta-iodobenzylguanidine uptake. Our experience has shown that [18F]-fluorodopamine is an excellent agent for localizing adrenal and extra-adrenal pheochromocytomas.

References

K. Pacak, M. D., Ph. D., D. Sc.

Unit of Clinical Neuroendocrinology · PREB · NICHD · NIH · Building 10 Room 9D42

MSC-1583 · 10 Center Drive · Bethesda · Maryland 20892 · USA ·

Phone: + 1 (301) 402-4594

Fax: + 1 (301) 402-4712

Email: karel@mail.nih.gov